Remifentanil for Smooth Emergence in Elderly Patients
Information source: Ajou University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Drug Usage
Intervention: Remifentanil (Drug); Remifentanil (Drug); Sevoflurane (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Ajou University School of Medicine Official(s) and/or principal investigator(s):
Jong Yeop Kim, Principal Investigator, Affiliation: Ajou University School of Medicine
Overall contact:
Jong Yeop KIm, Phone: 82-31-219-5574, Email: kjyeop@ajou.ac.kr
Summary
Elderly patients show different pharmacokinetic and pharmacodynamic variables and usually
need smaller doses of anaesthetic drugs than younger patients. The purpose of this study was
to investigate the optimal effect-site concentration of remifentanil for preventing cough
during emergence in elderly patients under sevoflurane and remifentanil anesthesia.
Clinical Details
Official title: Effect-site Concentration of Remifentanil for Preventing Cough During Emergence in Elderly Patients
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Primary outcome: Number of cough
Eligibility
Minimum age: 20 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ASA physical status I or II undergoing endoscopic sinus surgery or septoplasty under
balanced anesthesia with sevoflurane and remifentanil
Exclusion Criteria:
- predicted difficult airway, body mass index > 30 kg/m2, history of obstructive sleep
apnoea chronic respiratory disease or coughing, current smokers patients angiotensin
converting enzyme-inhibitors
Locations and Contacts
Jong Yeop KIm, Phone: 82-31-219-5574, Email: kjyeop@ajou.ac.kr Additional Information
Starting date: February 2015
Last updated: January 29, 2015
|
